The findings demonstrated the capacity of 4D5Fv-PE25 to recognize and inhibit HER2 targets effectively in vivo and in vivo, making it a highly suitable candidate drug for the management of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.